Figure 3. Reasons for Initial Androgen Receptor Inhibitor (ARI) Therapy Discontinuation as Assessed by the Treating Physician.

All percentages are rounded to the nearest integer. Other includes additional miscellaneous reasons, such as cost, physician decision, patient decision or withdrawal, rise in prostate-specific antigen level, and moved to oncology practice. AE indicates adverse event; mCRPC, metastatic castration-resistant prostate cancer.